182 related articles for article (PubMed ID: 26273188)
1. Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement.
Yum S; Jeong S; Lee S; Nam J; Kim W; Yoo JW; Kim MS; Lee BL; Jung Y
Drug Des Devel Ther; 2015; 9():4247-58. PubMed ID: 26273188
[TBL] [Abstract][Full Text] [Related]
2. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of rectal administration of muscovite on experimental colitis in rats.
Chen Y; Chen Y; Liu WL; Zhou TH; Cai JT; Du Q; Wang LJ; Wu JG; Si JM
J Gastroenterol Hepatol; 2009 May; 24(5):912-9. PubMed ID: 19220658
[TBL] [Abstract][Full Text] [Related]
4. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.
Laroui H; Dalmasso G; Nguyen HT; Yan Y; Sitaraman SV; Merlin D
Gastroenterology; 2010 Mar; 138(3):843-53.e1-2. PubMed ID: 19909746
[TBL] [Abstract][Full Text] [Related]
5. Use of artificial cell microcapsule containing thalidomide for treating TNBS-induced Crohn's disease in mice.
Fakhoury M; Coussa-Charley M; Al-Salami H; Kahouli I; Prakash S
Curr Drug Deliv; 2014; 11(1):146-53. PubMed ID: 24533726
[TBL] [Abstract][Full Text] [Related]
6. Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance.
Kang GD; Kim DH
J Ethnopharmacol; 2016 Aug; 189():175-85. PubMed ID: 27224242
[TBL] [Abstract][Full Text] [Related]
7. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
8. Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine.
Kim I; Kong H; Lee Y; Hong S; Han J; Jung S; Jung Y; Kim YM
Pharm Res; 2009 Feb; 26(2):415-21. PubMed ID: 18958401
[TBL] [Abstract][Full Text] [Related]
9. Mesalazine Activates Adenosine Monophosphate-activated Protein Kinase: Implication in the Anti-inflammatory Activity of this Anti-colitic Drug.
Park H; Kim W; Kim D; Jeong S; Jung Y
Curr Mol Pharmacol; 2019; 12(4):272-280. PubMed ID: 30848228
[TBL] [Abstract][Full Text] [Related]
10. Optimization of budesonide compression-coated tablets for colonic delivery.
Yehia SA; Elshafeey AH; Sayed I; Shehata AH
AAPS PharmSciTech; 2009; 10(1):147-57. PubMed ID: 19199041
[TBL] [Abstract][Full Text] [Related]
11. Coated chitosan pellets containing rutin intended for the treatment of inflammatory bowel disease: in vitro characteristics and in vivo evaluation.
Rabišková M; Bautzová T; Gajdziok J; Dvořáčková K; Lamprecht A; Pellequer Y; Spilková J
Int J Pharm; 2012 Jan; 422(1-2):151-9. PubMed ID: 22079717
[TBL] [Abstract][Full Text] [Related]
12. Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation.
Kim W; Kim S; Ju S; Lee H; Jeong S; Yoo JW; Yoon IS; Jung Y
Mol Pharm; 2019 Sep; 16(9):4007-4016. PubMed ID: 31386809
[TBL] [Abstract][Full Text] [Related]
13. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.
Lee Y; Kim W; Hong S; Park H; Yum S; Yoon JH; Jung Y
Eur J Pharmacol; 2014 Mar; 726():49-56. PubMed ID: 24462351
[TBL] [Abstract][Full Text] [Related]
14. Granisetron ameliorates acetic acid-induced colitis in rats.
Fakhfouri G; Rahimian R; Daneshmand A; Bahremand A; Rasouli MR; Dehpour AR; Mehr SE; Mousavizadeh K
Hum Exp Toxicol; 2010 Apr; 29(4):321-8. PubMed ID: 20154102
[TBL] [Abstract][Full Text] [Related]
15. 15-deoxyspergualin prevents mucosal injury by inhibiting production of TNF-alpha and down-regulating expression of MD-1 in a murine model of TNBS-induced colitis.
Lee J; Kim MS; Kim EY; Park HJ; Chang CY; Jung DY; Kwon CH; Joh JW; Kim SJ
Int Immunopharmacol; 2007 Aug; 7(8):1003-12. PubMed ID: 17570317
[TBL] [Abstract][Full Text] [Related]
16. Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/NF-κB signaling pathway.
Zeng Z; Zhan L; Liao H; Chen L; Lv X
Planta Med; 2013 Jan; 79(2):102-9. PubMed ID: 23250811
[TBL] [Abstract][Full Text] [Related]
17. Echinocystic acid, a metabolite of lancemaside A, inhibits TNBS-induced colitis in mice.
Hyam SR; Jang SE; Jeong JJ; Joh EH; Han MJ; Kim DH
Int Immunopharmacol; 2013 Feb; 15(2):433-41. PubMed ID: 23352442
[TBL] [Abstract][Full Text] [Related]
18. Targeting delivery of anti-TNFalpha oligonucleotide into activated colonic macrophages protects against experimental colitis.
Zuo L; Huang Z; Dong L; Xu L; Zhu Y; Zeng K; Zhang C; Chen J; Zhang J
Gut; 2010 Apr; 59(4):470-9. PubMed ID: 19951904
[TBL] [Abstract][Full Text] [Related]
19. Enhanced biopharmaceutical effects of tranilast on experimental colitis model with use of self-micellizing solid dispersion technology.
Kojo Y; Suzuki H; Kato K; Kaneko Y; Yuminoki K; Hashimoto N; Sato H; Seto Y; Onoue S
Int J Pharm; 2018 Jul; 545(1-2):19-26. PubMed ID: 29702241
[TBL] [Abstract][Full Text] [Related]
20. GPR120, a potential therapeutic target for experimental colitis in IL-10 deficient mice.
Zhao J; Wang H; Shi P; Wang W; Sun Y
Oncotarget; 2017 Jan; 8(5):8397-8405. PubMed ID: 28039475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
